PGF and wet macular degeneration: Aflibercept, the newest treatment option, is a fusion protein, with a high affinity for VEGF-A, VEGF-B and PlGF (placental growth factor), approved by the FDA in 2012, for the treatment of wet AMD, in a bimonthly regimen, after a loading phase of three monthly doses.